Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease
with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of …

Background Patients with connective tissue disease-associated pulmonary arterial
hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response …

BACKGROUND The purpose of this study was to compare patients with pulmonary arterial
hypertension enrolled in the AMBITION trial with (excluded from the primary analysis set [ex-…

Background In treatment-naive patients with pulmonary arterial hypertension, initial
combination therapy with ambrisentan and tadalafil reduces the risk of clinical failure events …

Objectives To evaluate initial combination therapy with ambrisentan plus tadalafil (COMB)
compared with monotherapy of either agent (MONO), and the utility of baseline characteristics …

BACKGROUND In the randomized, double-blind, event-driven AMBITION study, initial
combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of …

Background and objective Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease
that requires ongoing care and is associated with considerable socioeconomic burden. …

Background Initial combination therapy with ambrisentan and tadalafil reduced the risk of
clinical failure events for treatment-naïve participants with pulmonary arterial hypertension (…

BACKGROUND The multinational AMBITION study demonstrated a 50% risk reduction in
time to first clinical failure event (TtCF, a composite of death, hospitalization for worsening …